Document:

EX-10.2

 Exhibit 10.2 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b 
 AMENDED AND
RESTATED PRODUCT AGREEMENT 
 (INGREZZATM (valbenazine)) 

This Amended and Restated Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services
Agreement dated 28 November 2016 between Patheon UK Limited and Neurocrine Biosciences Inc. (the “Master Agreement”), and is entered into 27 June 2017 (the “Effective Date”), between Patheon UK Limited,
a corporation existing under the laws of England, having a principal place of business at Kingfisher Drive, Covingham, Swindon, SN3 5BZ, England (“Patheon”) and Neurocrine Biosciences Inc, 12780 El Camino Real, San Diego 92130,
California, USA (“Client”). 
 Each of Patheon and Client agree and acknowledge that the parties entered into a
Product Agreement dated 28 November 2016 (the “Prior Agreement”). As of the Effective Date, this Product Agreement amends and restates the Prior Agreement in its entirety; provided that any rights or obligations of either Patheon or
Client that were incurred prior to the Effective Date shall continue to be governed by the Prior Agreement. 
 The terms and conditions of
the Master Agreement are incorporated herein except to the extent this Product Agreement expressly references the specific provision in the Master Agreement to be modified by this Product Agreement. All capitalized terms that are used but not
defined in this Product Agreement will have the respective meanings given to them in the Master Agreement. 
 The Schedules to this Product
Agreement are incorporated into and will be construed in accordance with the terms of this Product Agreement. 
  

	 	1.	Product List and Specifications (See Schedule A attached hereto), which may be amended by Patheon and Client from time to time in a manually signed written document. 

 

	 	2.	Minimum Order Quantity, Annual Volume, and Price (See Schedule B attached hereto), which may be amended by Patheon and Client from time to time in a manually signed written document. 

 

	 	3.	Annual Stability Testing and Validation Activities (if applicable) (See Schedule C attached hereto), which may be amended by Patheon and Client from time to time in a manually signed written document.

  

	 	4.	Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto), which may be amended by Patheon and Client from time to time in a manually signed written document.

  

	 	5.	Yearly Forecasted Volume: [...***...] 

  
 *** Confidential Treatment Requested

  
 1 

	 	6.	Minimum Annual Revenue. as set out under Section 4.2.2 of the Master Agreement, Client shall be obliged to order and purchase an annual binding minimum amount of Product equal to USD$[...***...] (based
on small scale commercial manufacturing) or USD$[...***...] (based on full scale commercial manufacturing) as applicable. If in any Year the amount of Product purchased by Client is less than USD$[...***...] or
USD$[...***...] as applicable (i.e. payments of the Price received by Patheon) (“Actual Annual Purchase Amount”) then Client shall pay Patheon the shortfall between USD$[...***...] or USD$[...***...] as
applicable and the Actual Annual Purchase Amount. Patheon shall be entitled to invoice Client for any shortfall following 31 December of each Year. 

  

	 	7.	Territory: USA 

  

	 	8.	Manufacturing Site: the facility owned and operated by [...***...]. 

  

	 	9.	Inflation Index: pursuant to Section 4.2(a) of the Master Agreement, the inflation index is for France, “Indices de salaires mensuels de base des salaries de l’industrie pharmaceutique”,
published by Les Entreprises du médicament (LEEM) (for illustration:
http://www.leem.org/article/les-indices-des-salaires-de-lindustrie-pharmaceutique
). 

  

	 	10.	Initial Product Term: from the Effective Date until December 31, 2021. 

  

	 	11.	Notices: as set out under Section 13.9 of the Master Agreement 

  

	 	12.	Other Modifications to the Master Agreement: Not applicable 

  

 
 IN WITNESS
WHEREOF, the duly authorized representatives of the parties have executed this Product Agreement as of the Effective Date set forth above. 
  

			
	PATHEON UK LIMITED
		
	By:	 	 /s/ Mark Newton

	Name:	 	Mark Newton
	Title:	 	Senior Director Global Contract Services
		
	Date:	 	July 4, 2017
	
	NEUROCRINE BIOSCIENCES INC.
		
	By:	 	 /s/ David-Alexandre Gros

	Name:	 	David-Alexandre Gros
	Title:	 	President
		
	Date:	 	July 10, 2017

  
 *** Confidential Treatment Requested

  
 2 

 SCHEDULE A 

PRODUCT LIST AND SPECIFICATIONS 

[...***...] 

  
 *** Confidential Treatment Requested

  
 3 

 SCHEDULE B 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE 

[...***...] 

  
 *** Confidential Treatment Requested for
pages 4-8. 
 Omitted pages have been filed separately with the Commission. 
  

4 

 SCHEDULE C 

ANNUAL STABILITY TESTING 

[...***...] 

  
 *** Confidential Treatment Requested for
pages 9-10. 
 Omitted pages have been filed separately with the Commission. 
  

5 

 SCHEDULE D 

ACTIVE MATERIALS 

[...***...] 

  
 *** Confidential Treatment Requested

  
 6EX-10.3

 Exhibit 10.3 

SECOND AMENDMENT TO AMENDED AND RESTATED LEASE 

This SECOND AMENDMENT TO AMENDED AND RESTATED LEASE (“Second Amendment”) is made and entered into as of October 12,
2017, by and between KILROY REALTY, L.P., a Delaware limited partnership (“Landlord”), and NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (“Tenant”). 

R E C I T A L S : 

A. Landlord (as successor-in-interest to DMH CAMPUS INVESTORS,
LLC, a Delaware limited liability company) and Tenant are parties to that certain Amended and Restated Lease dated November 1, 2011 (the “Original Lease”), as amended by that certain First Amendment to Amended and
Restated Lease dated June 5, 2017 (the “First Amendment”), pursuant to which Tenant leases approximately 140,591 rentable square feet of space (and, as subject to re-measurement as set
forth in the First Amendment, the “Premises”) comprising the entirety of the building (the “Building”) located at 12780 El Camino Real, San Diego, California. The Original Lease as amended by the First Amendment is
referred to herein as the “Lease.” 
 B. Pursuant to Section 2.5 of the Work Letter (“Work
Letter”) attached to and incorporated in the First Amendment by reference, Tenant has elected to increase the Improvement Allowance (as defined in the First Amendment) by the amount of $1,410,910.00 (i.e. $10.00 per rentable square
foot of the Premises). 
 C. The parties desire to amend the Lease on the terms and conditions set forth in this Second Amendment, pursuant
to the requirements of Section 2.5 of the Work Letter. 
 A G R E E M E N
T : 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.
Terms. All capitalized terms when used herein shall have the same respective meanings as are given such terms in the Lease unless expressly provided otherwise in this Second Amendment. 

2. Additional Allowance. Pursuant to the terms of Section 2.5 of the Work Letter, Tenant is entitled to an
Additional Allowance of up to $1,410,910.00 (i.e., $10.00 per rentable square foot of the Premises). Notwithstanding any provision to the contrary contained in the Lease, Landlord and Tenant hereby acknowledge and agree that Tenant has elected to
utilize the entire $1,410,910.00 of the Additional Allowance, and accordingly the same shall be utilized and disbursed pursuant to the terms of the Work Letter and the total Improvement Allowance to which

  
 EXHIBIT C 

-1- 

 Tenant is entitled shall be $12,698,190.00. The term “Improvement Allowance” is hereby deemed to
refer to the amount of $12,698.190.00 (i.e. $90.00 per rentable square foot of the Premises). 
 3. Monthly Rental.
Pursuant to the terms of Section 2.5 of the Work Letter, as a result of Tenant’s use of the entire Additional Allowance pursuant to Section 2 above, the initial Monthly Rental rate per square foot for the Premises shall
be increased by $0.05, and accordingly Section 4 of the First Amendment shall be amended per the terms below. 
 3.1
Monthly Rental Before Extended Term. Effective as of the date of this Second Amendment, the Monthly Rental schedule set forth in Section 4.1 of the First Amendment is hereby deleted in its entirety and replaced with the
following: 
  

							
	 “Period During Original Term
	  	Annualized
Rental	  	Monthly Rental	  	Monthly Rental Rate
per Square Foot
				
	June 1, 2017 – May 31, 2018*	  	$5,989,176.60	  	$499,098.05	  	$3.55
				
	June 1, 2018 – May 31, 2019	  	$6,168,851.90	  	$514,070.99	  	$3.66
				
	June 1, 2019 – December 31, 2019	  	$6,353,917.45	  	$529,493.12	  	$3.77

  

	 	*	Subject to the terms set forth in Section 4.3 of the First Amendment (as amended by this Second Amendment), the Monthly Rental attributable to the three (3) month period commencing on July 1, 2017
and ending on September 30, 2017 shall be abated.” 

 3.2 Monthly Rental During Extended Term.
Effective as of the date of this Second Amendment, the Monthly Rental schedule set forth in Section 4.2 of the First Amendment is hereby deleted in its entirety and replaced with the following: 

 

							
	 “Period During Extended Term
	  	Annualized
Rental	  	Monthly Rental	  	Monthly Rental Rate
per Square Foot
				
	January 1, 2020 – May 31, 2020	  	$6,376,514.62	  	$531,376.22	  	$3.77
				
	June 1, 2020 – May 31, 2021	  	$6,567,810.06	  	$547,317.51	  	$3.88
				
	June 1, 2021 – May 31, 2022	  	$6,764,844.37	  	$563,737.03	  	$4.00
				
	June 1, 2022 – May 31, 2023	  	$6,967,789.70	  	$580,649.14	  	$4.12

  
 EXHIBIT C 

-2- 

							
				
	June 1, 2023 – May 31, 2024	  	$7,176,823.39	  	$598,068.62	  	$4.24
				
	June 1, 2024 – May 31, 2025	  	$7,392,128.09	  	$616,010.67	  	$4.37
				
	June 1, 2025 – May 31, 2026	  	$7,613,891.93	  	$634,490.99	  	$4.50
				
	June 1, 2026 – May 31, 2027	  	$7,842,308.69	  	$653,525.72	  	$4.63
				
	June 1, 2027 – May 31, 2028	  	$8,077,577.95	  	$673,131.50	  	$4.77
				
	June 1, 2028 – May 31, 2029	  	$8,319,905.29	  	$693,325.44	  	$4.91
				
	June 1, 2029 – December 31, 2029	  	$8,569,502.45	  	$714,125.20	  	$5.06”

 Abated Monthly Rental. Effective as of the date of this Second Amendment,
Section 4.3 of the First Amendment is hereby deleted in its entirety and replaced with the following: 

“4.3 Abated Monthly Rental. Provided that Tenant is not then in default of the Lease (as hereby amended)
(beyond the expiration of any applicable notice and cure period set forth in the Lease, as amended), then during the three (3) month period commencing on July 1, 2017 and ending on September 30, 2017 (the “Rent Abatement
Period”), Tenant shall not be obligated to pay any Monthly Rental otherwise attributable to the Premises during such Rent Abatement Period (the “Rent Abatement”). Landlord and Tenant acknowledge that the aggregate amount of
the Rent Abatement equals $1,497,294.15 (i.e., $499,098.05 per month). Tenant acknowledges and agrees that during such Rent Abatement Period, such abatement of Monthly Rental for the Premises shall have no effect on the calculation of any
future increases in Monthly Rental, Operating Expenses or Taxes payable by Tenant pursuant to the terms of the Lease, which increases shall be calculated without regard to such Rent Abatement. Additionally, Tenant shall be obligated to pay all
Additional Rental during the Rent Abatement Period. Tenant acknowledges and agrees that the foregoing Rent Abatement has been granted to Tenant as additional consideration for entering into this First Amendment, and for agreeing to pay the rent and
perform the terms and conditions otherwise required under the Lease (as hereby amended). If Tenant shall be in default under the Lease (as hereby amended) and shall fail to cure such default within the notice and cure period, if any, permitted for
cure pursuant to the Lease (as hereby amended), or if the Lease (as hereby amended) is terminated for any reason, other than as the result of casualty or condemnation, then the dollar amount of the unapplied portion of the

  
 EXHIBIT C 

-3- 

 
Rent Abatement as of such default or termination shall be converted to a credit to be applied to the Monthly Rental applicable at the end of the Extended Term and Tenant shall immediately be
obligated to begin paying Monthly Rental for the Premises in full.” 
 4. California Accessibility Disclosure. For
purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges that the Common Areas and the Premises have not undergone inspection by a Certified Access Specialist (CASp). 

5. No Broker. Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or
agent in connection with the negotiation of this Second Amendment, and that they know of no real estate broker or agent who is entitled to a commission in connection with this Second Amendment. Without limiting the foregoing, Landlord agrees to pay
the commission, if any, claimed or alleged to be owed by Cushman & Wakefield, Landlord’s broker in connection with the First Amendment. Each party agrees to indemnify and defend the other party against and hold the other party harmless
from any and all claims, demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys’ fees) with respect to any leasing commission or equivalent compensation alleged to be owing on
account of any use or dealings with any real estate broker or agent, occurring by, through, or under the indemnifying party. The terms of this Section 5 shall survive the expiration or earlier termination of the term of the Lease, as
hereby amended. 
 6. No Further Modification. Except as specifically set forth in this Second Amendment, all of the
terms and provisions of the Lease shall remain unmodified and in full force and effect. 
 [signatures contained on following page] 

  
 EXHIBIT C 

-4- 

 IN WITNESS WHEREOF, this Second Amendment has been executed as of the day and year first above
written. 
  

					
	“LANDLORD”:
	
	 KILROY REALTY, L.P.,

a Delaware limited partnership

		
	 By:
	 	 Kilroy Realty Corporation,

		 	 a Maryland corporation

			
		 	 Its:
	 	 General Partner

			
		 	 By:
	 	 /s/ Jeffrey C. Hawken

			
		 	 Name:
	 	 Jeffrey C. Hawken

			
		 	 Its:
	 	 EVP and Chief Operating Officer

			
		 	 By:
	 	 /s/ Nelson Ackerly

			
		 	 Name:
	 	 Nelson Acklerly

			
		 	 Its:
	 	 SVP San Diego

	
	“TENANT”:
	
	 NEUROCRINE BIOSCIENCES, INC.,

a Delaware corporation

		
	By:	 	 /s/ Darin Lippoldt

		
	Name:	 	 Darin Lippoldt

		
	Its:	 	 Chief Legal Officer

		
	By:	 	 /s/ Tim Coughlin

		
	Name:	 	 Tim Coughlin

		
	Its:	 	 VP, Finance

  
 EXHIBIT C 

-5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]